Compare Invesco S&P 500 Momentum ETF (SPMO) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco S&P 500 Momentum ETF vs Travere Therapeutics Inc. Common Stock — how do they compare? Invesco S&P 500 Momentum ETF trades at $143.87 (market cap $23.04B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Invesco S&P 500 Momentum ETF is far larger — about 4.7× Travere Therapeutics Inc. Common Stock's market cap, and Invesco S&P 500 Momentum ETF is more actively traded (2,008,654 versus 1,668,577). Which is the better fit depends on your goals — on Pluang, investors hold Invesco S&P 500 Momentum ETF for 55 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| SPMO | TVTX | |
|---|---|---|
Market Cap | $23.04B | $4.88B |
Volume | 2,008,654 | 1,668,577 |
Sector | Broad Market / Factor | Health |
52-Week High | $161.66 | $67.52 |
52-Week Low | $107.84 | $26.79 |
Typical Hold Time | 55 Days | 0 Days |
Enterprise Value | — | $5.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SPMO, the Invesco S&P 500 Momentum ETF, trades at $148.03, down 0.89% on the day amid a bearish technical signal. The ETF recently completed its semi-annual reconstitution, adding 54 stocks including Apple and Merck while removing Nvidia. Its momentum strategy has historically outperformed the S&P 500 but faces near-term volatility from concentrated sector exposure.
Outlook remains mixed with strong long-term momentum performance offset by current technical weakness. Investment opportunity lies in capturing S&P 500's fastest-rising stocks, though risks include high volatility and sector concentration. The ETF's structural edge suggests potential for continued outperformance despite recent underperformance.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Invesco S&P 500 Momentum ETF
SPMO is designed to track the investment results of the S&P 500 Momentum Index. This index measures the performance of stocks in the S&P 500 that exhibit the highest momentum, or the greatest price appreciation, over the trailing 12 months, while excluding the most recent month. By investing in these high-momentum stocks, SPMO seeks to capitalize on the historical trend that stocks with strong recent performance tend to continue that performance in the near term, offering a systematic approach to factor investing within the large-cap U.S. equity market.
Read more on SPMO →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
